Akshit Sharma, MD
Interventional Cardiology · Chandler, AZNPI 1205256518
Payments from drug & device makers
Across 106 payments — averaging $121.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$6K
- Boston Scientific$2K
- Penumbra, Inc.$2K
- Medtronic$461
- Shockwave Medical, Inc$369
- Philips North America LLC$347
- plus $2K from 25 others
What the payments were for
- Grants$1,64113%
- Travel & lodging$1,0728%
- Food & beverage$4,65636%
- Other$5,45843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 6 | $6,039 |
| Boston Scientific | 9 | $2,185 |
| Penumbra, Inc. | 3 | $1,658 |
| Medtronic(2 entities) | 8 | $461 |
| Shockwave Medical, Inc | 3 | $369 |
| Philips North America LLC | 6 | $347 |
| Abbott | 3 | $277 |
| Pfizer | 15 | $257 |
| Biotronik Inc. | 3 | $184 |
| Abiomed | 5 | $129 |
| Bard Peripheral Vascular, Inc. | 4 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $109 |
| Novartis | 6 | $91 |
| Merck | 4 | $70 |
| Amgen | 4 | $67 |
| Johnson & Johnson | 4 | $54 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $54 |
| BD | 1 | $50 |
| Cardiva Medical, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Novo Nordisk | 2 | $34 |
| Lilly USA, LLC | 2 | $25 |
| Edwards Lifesciences | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Inari Medical, Inc. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$5,829
- Indigo System$1,658
- GENERAL - STRUCTURAL HEART$1,105
- GENERAL ATHERECTOMY$536
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$295
- Supera peripheral stent system$253
- ANGIOJET$182
- SYMPLICITY G3$159
- General - Balloon Catheters$147
- Turbo Elite$125
- Resolute$116
- DISEASE STATE$109
- (5027) Intact Vascular Und$105
How this compares
$12,826 in reported general payments places this provider in the 50th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,009 | $901,039 |
| Repatha SureclickEvolocumab | 446 | $310,796 |
| JardianceEmpagliflozin | 289 | $245,113 |
| EntrestoSacubitril/Valsartan | 201 | $193,585 |
| XareltoRivaroxaban | 162 | $139,497 |
| BrilintaTicagrelor | 156 | $100,948 |
| Praluent PenAlirocumab | 103 | $59,352 |
| FarxigaDapagliflozin Propanediol | 64 | $53,748 |
| Ranolazine ErRanolazine | 579 | $46,267 |
| NexletolBempedoic Acid | 71 | $34,986 |
| Ezetimibe | 1,337 | $22,327 |
| Rosuvastatin Calcium | 2,173 | $21,011 |
| VascepaIcosapent Ethyl | 24 | $18,373 |
| Prasugrel Hcl | 231 | $16,818 |
| Metoprolol Succinate | 1,492 | $16,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $257 | $901,0391,009 claims |
| Boehringer IngelheimJardiance | $17 | $245,113289 claims |
| NovartisEntresto | $91 | $193,585201 claims |
| Johnson & JohnsonXarelto | $54 | $139,497162 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $13 | $49,28795 claims |
| AmgenCorlanor | $67 | $12,28620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Chandler
- Ashish PershadChandler$1.4M
- Prakash BalanChandler$321K
- Georges NseirChandler$296K
- Pratik DalalChandler$142K
- Abhishek SawantChandler$81K
- Kush AgrawalChandler$44K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.